UCL and Takeda announce a new research partnership
Aims the identification of novel therapeutic targets for neurodegenerative diseases
This collaboration will focus on mechanistic approaches for the identification of genes or signalling pathways that modify neurodegenerative disease processes affecting neuronal health (for example motor neurone disease (MND or ALS), Huntington’s disease and Parkinson’s disease). The collaboration, which includes support from the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre, will initially run for a three-year period. It will be carried out by Takeda Cambridge Limited, Takeda’s research unit based in Cambridge, UK.
Dr. Tetsuyuki Maruyama, General Manager of Takeda’s Pharmaceutical Research Division said: “At Takeda, we work with partners to accelerate innovation. We are looking forward to collaborating with UCL’s world-class researchers. This cooperation will help us to identify and validate novel therapeutic pathways in central nervous system diseases, which is one of Takeda’s core therapeutic areas – ultimately leading to new treatments for patients suffering from neurodegenerative disorders.”
Professor Nicholas Wood, Neuroscience Programme Director at the NIHR University College London Hospitals Biomedical Research Centre, said: “I am delighted and excited with the potential of this initiative. It combines Takeda’s strengths in central nervous system (CNS) therapeutics with our research at UCL but importantly focuses on projects with huge experimental medicine potential".
Professor Alan Thompson, Dean of the Faculty of Brain Sciences, UCL said: “Developing new treatments for devastating neurodegenerative diseases is an absolutely essential but very challenging goal and requires the complementary expertise of academia and industry, if it is to be achieved. This UCL-Takeda collaboration represents just such a partnership and as Dean of the Faculty of Brain Sciences, I am delighted to see it evolving so well.”
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.